Sanofi (SNYNF) Short-term Investments (2009 - 2021)
Sanofi's (SNYNF) quarterly Short-term Investments came in at $12.5 million in Q4 2021, down 93.18% year-on-year from $182.9 million in Q4 2020, and down 93.18% quarter-over-quarter from $182.9 million in Q4 2020.
Sanofi (SNYNF) Short-term Investments (2009 - 2021) Analysis & Trends
Sanofi has disclosed Short-term Investments across 13 years of filings, most recently posting $12.5 million for Q4 2021.
- Short-term Investments for Q4 2021 came in at $12.5 million, down 93.18% year-over-year; the trailing twelve-month figure through Dec 2021 was $12.5 million (down 93.18% YoY), and the FY2021 annual result was $12.9 million, down 92.64% from the prior year.
- Short-term Investments came in at $12.5 million for Q4 2021 at Sanofi, down from $182.9 million in the prior quarter.
- In the past five years, Short-term Investments ranged from a high of $227.1 million in Q4 2018 to a low of $12.5 million in Q4 2021.
- The 5-year median for Short-term Investments is $147.0 million (2019), against an average of $132.0 million.
- Across the five-year window, Short-term Investments surged 170.86% in 2017 and slumped 93.18% in 2021, its largest moves.
- Sanofi's Short-term Investments stood at $90.7 million in 2017, then jumped by 150.53% to $227.1 million in 2018, then plunged by 35.28% to $147.0 million in 2019, then climbed by 24.42% to $182.9 million in 2020, then slumped by 93.18% to $12.5 million in 2021.
- The last three Short-term Investments figures came in at $12.5 million (Q4 2021), $182.9 million (Q4 2020), and $147.0 million (Q4 2019), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn |
| 10 | Sanofi | - | - | 9.49 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 12.47 Mn |
| Dec 31, 2020 | 182.90 Mn |
| Dec 31, 2019 | 146.99 Mn |
| Dec 31, 2018 | 227.14 Mn |
| Dec 31, 2017 | 90.66 Mn |
| Dec 31, 2016 | 33.47 Mn |
| Jun 30, 2016 | 146.88 Mn |
| Dec 31, 2015 | 14.25 Mn |
| Jun 30, 2015 | 249.76 Mn |
| Dec 31, 2014 | 272.46 Mn |
| Jun 30, 2014 | 93.29 Mn |
| Dec 31, 2013 | 251.80 Mn |
| Jun 30, 2013 | 107.07 Mn |
| Dec 31, 2012 | 230.85 Mn |
| Jun 30, 2012 | 425.31 Mn |
| Dec 31, 2011 | 233.15 Mn |
| Jun 30, 2011 | 165.43 Mn |
| Dec 31, 2010 | 69.26 Mn |
| Jun 30, 2010 | 230.75 Mn |
| Dec 31, 2009 | 409.06 Mn |